阅读说明：本技术 用于抑制肝脂肪合成的食品组合物 (Food composition for inhibiting liver fat synthesis ) 是由 井上启 木村久美 橘伸彦 于 2020-02-20 设计创作，主要内容包括：本发明提供作为具有抑制肝脂肪合成作用成分的选自11种二肽(Ala-Gly、His-Asn、His-Ser、His-Thr、His-Trp、Val-Met、Trp-Glu、Trp-Lys、Tyr-Lys、Tyr-Ser及Tyr-Tyr)及25种三肽(Val-Ile-Leu、Gly-Ser-Leu、Val-Leu-Gln、His-Ala-Gln、Arg-Ala-Val、Lys-Leu-Gly、Ile-Val-Ile、Lys-Pro-Ile、Leu-Val-Ile、Leu-Arg-Asp、Gln-Glu-Glu、Ser-Gly-Glu、Arg-Trp-Phe、Asp-Phe-Phe、Asp-Val-Phe、Pro-Phe-Tyr、Phe-Ile-Arg、Asn-Gly-Arg、Ile-Ile-Pro、Ile-Asp-Arg、Ile-His-Arg、Ile-Asp-Arg、Asn-Arg-Val、Ser-Ser-Val及Val-Phe-Val)中的一种或两种以上的肽。所述肽可以在用于抑制肝脂肪合成的食品组合物及肝脂肪合成抑制剂中使用。(The present invention provides a composition having an inhibitory activity against hepatic fat synthesis, which is selected from 11 dipeptides (Ala-Gly, His-Asn, His-Ser, His-Thr, His-Trp, Val-Met, Trp-Glu, Trp-Lys, Tyr-Ser and Tyr-Tyr) and 25 tripeptides (Val-Ile-Leu, Gly-Ser-Leu, Val-Leu-Gln, His-Ala-Gln, Arg-Ala-Val, Lys-Leu-Gly, Ile-Val-Ile, Lys-Pro-Ile, Leu-Val-Ile, Leu-Arg-Asp, Gln-Glu-Glu, Ser-Gly-Glu, Arg-Trp-Phe, Asp-Phe-Phe, Asp-Val-Phe-Phe, Pro-Phe-Tyr, Leu-Phe-Tyr, Phe-Ile-Arg, Asn-Gly-Arg, Ile-Ile-Pro, Ile-Asp-Arg, Ile-His-Arg, Ile-Asp-Arg, Asn-Arg-Val, Ser-Ser-Val and Val-Phe-Val). The peptide can be used in food compositions for inhibiting liver fat synthesis and liver fat synthesis inhibitors.)

1. Selected from Ala-Gly, His-Asn, His-Ser, His-Thr, His-Trp, Val-Met, Trp-Glu, Trp-Lys, Tyr-Ser, Tyr-Tyr, Val-Ile-Leu, Gly-Ser-Leu, Val-Leu-Gln, His-Ala-Gln, Arg-Ala-Val, Lys-Leu-Gly, Ile-Val-Ile, Lys-Pro-Ile, Leu-Val-Ile, Leu-Arg-Asp, Gln-Glu-Glu, Ser-Gly-Glu, Arg-Trp-Phe, Asp-Phe-Phe, Asp-Val-Phe, Pro-Phe-Tyr, Phe-Ile-Arg, Asn-Gly-Arg, Ile-Pro, Pro-Phe-Glu-Glu, Arg, Ile-Gly-, Use of one or more peptides selected from Ile-Asp-Arg, Ile-His-Arg, Ile-Asp-Arg, Asn-Arg-Val, Ser-Ser-Val and Val-Phe-Val for the manufacture of a food composition for inhibiting liver fat synthesis.

2. Use of one or more dipeptides selected from Ala-Gly, His-Asn, His-Ser, His-Thr, His-Trp, Val-Met, Trp-Glu, Trp-Lys, Tyr-Ser and Tyr-Tyr for the manufacture of a food composition for inhibiting liver fat synthesis.

3. Selected from Val-Ile-Leu, Gly-Ser-Leu, Val-Leu-Gln, His-Ala-Gln, Arg-Ala-Val, Lys-Leu-Gly, Ile-Val-Ile, Lys-Pro-Ile, Leu-Val-Ile, Leu-Arg-Asp, Gln-Glu-Glu, Ser-Gly-Glu, use of one or more tripeptides of Arg-Trp-Phe, Asp-Phe-Phe, Asp-Val-Phe, Pro-Phe-Tyr, Phe-Ile-Arg, Asn-Gly-Arg, Ile-Ile-Pro, Ile-Asp-Arg, Ile-His-Arg, Ile-Asp-Arg, Asn-Arg-Val, Ser-Ser-Val and Val-Phe-Val for the manufacture of a food composition for inhibiting liver fat synthesis.

4. Selected from Ala-Gly, His-Asn, His-Ser, His-Thr, His-Trp, Val-Met, Trp-Glu, Trp-Lys, Tyr-Ser, Tyr-Tyr, Val-Ile-Leu, Gly-Ser-Leu, Val-Leu-Gln, His-Ala-Gln, Arg-Ala-Val, Lys-Leu-Gly, Ile-Val-Ile, Lys-Pro-Ile, Leu-Val-Ile, Leu-Arg-Asp, Gln-Glu-Glu, Ser-Gly-Glu, Arg-Trp-Phe, Asp-Phe-Phe, Asp-Val-Phe, Pro-Phe-Tyr, Phe-Ile-Arg, Asn-Gly-Arg, Ile-Pro, Pro-Phe-Glu-Glu, Arg, Ile-Gly-, Use of one or more peptides selected from Ile-Asp-Arg, Ile-His-Arg, Ile-Asp-Arg, Asn-Arg-Val, Ser-Ser-Val and Val-Phe-Val for producing an inhibitor for liver fat synthesis.

5. Use of a dipeptide selected from the group consisting of Ala-Gly, His-Asn, His-Ser, His-Thr, His-Trp, Val-Met, Trp-Glu, Trp-Lys, Tyr-Ser and Tyr-Tyr, or a combination thereof, for the manufacture of an inhibitor for hepatic fat synthesis.

6. Selected from Val-Ile-Leu, Gly-Ser-Leu, Val-Leu-Gln, His-Ala-Gln, Arg-Ala-Val, Lys-Leu-Gly, Ile-Val-Ile, Lys-Pro-Ile, Leu-Val-Ile, Leu-Arg-Asp, Gln-Glu-Glu, Ser-Gly-Glu, use of one or more tripeptides of Arg-Trp-Phe, Asp-Phe-Phe, Asp-Val-Phe, Pro-Phe-Tyr, Phe-Ile-Arg, Asn-Gly-Arg, Ile-Ile-Pro, Ile-Asp-Arg, Ile-His-Arg, Ile-Asp-Arg, Asn-Arg-Val, Ser-Ser-Val and Val-Phe-Val for producing an inhibitor for liver fat synthesis.

Technical Field

The present invention relates to a peptide having an inhibitory activity on liver fat synthesis, a food composition for inhibiting liver fat synthesis containing the peptide, and an inhibitor of liver fat synthesis, and a method for inhibiting liver fat synthesis.

Background

Fatty liver is known to cause a vicious circle with diabetes and cardiovascular diseases. As a cause of fatty liver, an increase in liver fat synthesis plays an important role, and a liposynthase is known as a control mechanism thereof.

For prevention and improvement of fatty liver, it is effective to suppress synthesis of lipid in liver and to enhance lipid metabolism and to suppress accumulation.

In recent years, various functional components derived from natural sources have been studied, and there have been reports of components that act on lipid metabolism to reduce the amount of lipids in the liver. Patent documents 1 and 2 disclose that dried and crushed products of soybean protein or plant sprouts have an effect of reducing neutral fat in blood. However, in these documents, an inhibitory effect on fat accumulation in the liver has not been confirmed.

Further, it has been found that the uptake of plant proteins improves fatty liver by inhibiting the expression of lipoxygenase, and that the peptide decomposition products thereof cause the inhibition of the expression of lipoxygenase in liver cells (non-patent document 1).

Disclosure of Invention

Problems to be solved by the invention

In the prior art, there is no disclosure of any component showing an inhibitory effect on hepatic fat synthesis.

In one embodiment, the present invention aims to provide a component having an inhibitory effect on hepatic fat synthesis. In some embodiments, it is an object of the present invention to provide a food composition comprising an ingredient having an inhibitory effect on liver fat synthesis. In another embodiment, the present invention aims to provide an inhibitor for liver fat synthesis comprising a component having an inhibitory effect on liver fat synthesis. In other embodiments, it is an object of the present invention to provide methods of inhibiting hepatic fat synthesis.

Means for solving the problems

The present inventors have conducted intensive studies to solve the above problems and, as a result, have found that specific dipeptides and tripeptides have a liver fat synthesis inhibitory effect, and have completed the present invention.

That is, the present invention relates to

(1) A food composition for inhibiting liver fat synthesis, which comprises as an active ingredient a compound selected from the group consisting of Ala-Gly, His-Asn, His-Ser, His-Thr, His-Trp, Val-Met, Trp-Glu, Trp-Lys, Tyr-Ser, Tyr-Tyr, Val-Ile-Leu, Gly-Ser-Leu, Val-Leu-Gln, His-Ala-Gln, Arg-Ala-Val, Lys-Leu-Gly, Ile-Val-Ile, Lys-Pro-Ile, Leu-Val-Ile, Leu-Arg-Asp, Gln-Glu, Ser-Gly-Glu, Arg-Trp-Phe, Asp-Phe-Phe, Asp-Val-Phe-Phe, Pro-Phe-Tyr, Leu-Ser-Leu-, One or more than two of Phe-Ile-Arg, Asn-Gly-Arg, Ile-Ile-Pro, Ile-Asp-Arg, Ile-His-Arg, Ile-Asp-Arg, Asn-Arg-Val, Ser-Ser-Val and Val-Phe-Val,

(2) a food composition for suppressing liver fat synthesis, which comprises as an active ingredient one or more dipeptides selected from Ala-Gly, His-Asn, His-Ser, His-Thr, His-Trp, Val-Met, Trp-Glu, Trp-Lys, Tyr-Ser, and Tyr-Tyr,

(3) a food composition for inhibiting liver fat synthesis, which comprises as an active ingredient a compound selected from the group consisting of Val-Ile-Leu, Gly-Ser-Leu, Val-Leu-Gln, His-Ala-Gln, Arg-Ala-Val, Lys-Leu-Gly, Ile-Val-Ile, Lys-Pro-Ile, Leu-Val-Ile, Leu-Arg-Asp, Gln-Glu-Glu, Ser-Gly-Glu, Arg-Trp-Phe, Asp-Phe-Phe, Asp-Val-Phe, Pro-Phe-Tyr, Phe-Ile-Arg, Asn-Gly-Arg, Ile-Ile-Pro, Ile-Asp-Arg, Ile-His-Arg, Ile-Asp-Arg, Asn-Arg-Val, Gly-Arg, One or more tripeptides selected from Ser-Ser-Val and Val-Phe-Val,

(4) an inhibitor for hepatic fat synthesis which comprises as the active ingredient a compound selected from the group consisting of Ala-Gly, His-Asn, His-Ser, His-Thr, His-Trp, Val-Met, Trp-Glu, Trp-Lys, Tyr-Ser, Tyr-Tyr, Val-Ile-Leu, Gly-Ser-Leu, Val-Leu-Gln, His-Ala-Gln, Arg-Ala-Val, Lys-Leu-Gly, Ile-Val-Ile, Lys-Pro-Ile, Leu-Val-Ile, Leu-Arg-Asp, Gln-Glu-Glu, Ser-Gly-Glu, Arg-Trp-Phe, Asp-Phe-Phe, Asp-Val-Phe-Phe, Pro-Phe-Tyr, Phe-Ile-Arg, Arg-Gln-Glu-Glu, One or more than two of Asn-Gly-Arg, Ile-Ile-Pro, Ile-Asp-Arg, Ile-His-Arg, Ile-Asp-Arg, Asn-Arg-Val, Ser-Ser-Val and Val-Phe-Val,

(5) a hepatic fat synthesis inhibitor comprising as an active ingredient one or more dipeptides selected from Ala-Gly, His-Asn, His-Ser, His-Thr, His-Trp, Val-Met, Trp-Glu, Trp-Lys, Tyr-Ser, and Tyr-Tyr,

(6) an inhibitor for hepatic fat synthesis which comprises as the active ingredient a compound selected from the group consisting of Val-Ile-Leu, Gly-Ser-Leu, Val-Leu-Gln, His-Ala-Gln, Arg-Ala-Val, Lys-Leu-Gly, Ile-Val-Ile, Lys-Pro-Ile, Leu-Val-Ile, Leu-Arg-Asp, Gln-Glu-Glu, Ser-Gly-Glu, Arg-Trp-Phe, Asp-Phe-Phe, Asp-Val-Phe, Pro-Phe-Tyr, Phe-Ile-Arg, Asn-Gly-Arg, Ile-Ile-Pro, Ile-Asp-Arg, Ile-His-Arg, Ile-Asp-Arg, Asn-Arg-Val, Ser-Ser-Val and Val-Phe-Val.

ADVANTAGEOUS EFFECTS OF INVENTION

In one embodiment, a peptide having an inhibitory effect on liver fat synthesis can be provided according to the present invention. In some embodiments, a food composition containing a specific peptide having an inhibitory effect on liver fat synthesis as an active ingredient can be provided according to the present invention. In other embodiments, a liver fat synthesis inhibitor containing a specific peptide as an active ingredient can be provided. In addition, in other embodiments, methods of inhibiting hepatic fat synthesis may be provided.

Drawings

FIG. 1A reference drawing of the method for making Fasn reporter mice in 1 selection.

FIG. 2 is a graph showing the results of measuring the relative activity values of gaussianic luciferases (gaussianuciferases) obtained by 1-time screening of dipeptides of dipeptide libraries (#1 to #50) with respect to a blank. The relative activity values for each sample are represented by a circle symbol, with filled circles showing samples that show significantly lower values compared to the blank.

FIG. 3 is a graph showing the activity of 1-time-screened Gauss luciferases corresponding to dipeptides of dipeptide libraries (#51 to #100), and the results of measuring the relative activity values thereof with respect to blanks. The relative activity values for each sample are represented by a circle symbol, with filled circles showing samples that show significantly lower values compared to the blank.

FIG. 4 is a graph showing the results of measuring relative activity values of 1-time screened Gaussian luciferases corresponding to dipeptides of dipeptide libraries (#101 to #150) with respect to a blank. The relative activity values for each sample are represented by a circle symbol, with filled circles showing samples that show significantly lower values compared to the blank.

FIG. 5 is a graph showing the results of measuring relative activity values of 1-time screened Gaussian luciferases corresponding to dipeptides of dipeptide libraries (#151 to #200) with respect to a blank. The relative activity values for each sample are represented by a circle symbol, with filled circles showing samples that show significantly lower values compared to the blank.

FIG. 6 is a graph showing the results of measuring relative activity values of 1-time screened Gaussian luciferases corresponding to dipeptides of dipeptide libraries (#201 to #250) with respect to a blank. The relative activity values for each sample are represented by a circle symbol, with filled circles showing samples that show significantly lower values compared to the blank.

FIG. 7 is a graph showing the results of measuring relative activity values of 1-time screened Gaussian luciferases corresponding to dipeptides of dipeptide libraries (#251 to #300) with respect to a blank. The relative activity values for each sample are represented by a circle symbol, with filled circles showing samples that show significantly lower values compared to the blank.

FIG. 8 is a graph showing the activity of 1-time-screened Gauss luciferases corresponding to dipeptides of dipeptide libraries (#301 to #336), and the results of measuring the relative activity values thereof with respect to blanks. The relative activity values for each sample are represented by a circle symbol, with filled circles showing samples that show significantly lower values compared to the blank.

FIG. 9 shows the results of measuring the expression level of Fasn gene in 2 screens of 22 dipeptides. The black bar shows samples with a significant decrease in the expression of the Fasn gene compared to the blank (described as Veh).

FIG. 10 shows the results of measuring the expression level of Fasn gene in 3 screens of 11 dipeptides. The black bar shows samples with a significant decrease in the expression of the Fasn gene compared to the blank (described as Veh).

FIG. 11 shows the results of measuring the expression level of Fasn gene in 3 screens of 11 dipeptides. The black bar shows samples with a significant decrease in the expression of the Fasn gene compared to the blank (described as Veh).

FIG. 12 is a graph showing the results of measuring the relative activity values of 1-time screened Gaussian luciferases with respect to the tripeptides of the tripeptide library (#1 to #50) conceived from the amino acid sequence of α -8S globulin with respect to the blank. The relative activity values for each sample are represented by a circle symbol, with filled circles showing samples that show significantly lower values compared to the blank.

FIG. 13 is a graph showing the results of measuring the relative activity values of 1-time screened Gaussian luciferases with respect to the tripeptides of the tripeptide library (#51 to #100) conceived from the amino acid sequence of α -8S globulin with respect to the blank. The relative activity values for each sample are represented by a circle symbol, with filled circles showing samples that show significantly lower values compared to the blank.

FIG. 14 is a graph showing the results of measuring the relative activity values of 1-time screened Gaussian luciferases with respect to the tripeptides of the tripeptide library (#101 to #150) conceived from the amino acid sequence of α -8S globulin, relative to the blank. The relative activity values for each sample are represented by a circle symbol, with filled circles showing samples that show significantly lower values compared to the blank.

FIG. 15 is a graph showing the results of measuring the relative activity values of 1-time screened Gaussian luciferases with respect to the tripeptides of the tripeptide library (#151 to #200) conceived from the amino acid sequence of α -8S globulin, relative to the blank. The relative activity values for each sample are represented by a circle symbol, with filled circles showing samples that show significantly lower values compared to the blank.

FIG. 16 is a graph showing the results of measuring the relative activity values of 1-time screened Gaussian luciferases with respect to the tripeptides of the tripeptide library (#201 to #250) conceived from the amino acid sequence of α -8S globulin, relative to the blank. The relative activity values for each sample are represented by a circle symbol, with filled circles showing samples that show significantly lower values compared to the blank.

FIG. 17 is a graph showing the results of measuring the relative activity values of 1-time screened Gaussian luciferases with respect to the tripeptides of the tripeptide library (#251 to #300) conceived from the amino acid sequence of α -8S globulin with respect to the blank. The relative activity values for each sample are represented by a circle symbol, with filled circles showing samples that show significantly lower values compared to the blank.

FIG. 18 is a graph showing the results of measuring the relative activity values of 1-time screened Gaussian luciferases with respect to the tripeptides of the tripeptide library (#301 to #350) conceived from the amino acid sequence of α -8S globulin, relative to the blank. The relative activity values for each sample are represented by a circle symbol, with filled circles showing samples that show significantly lower values compared to the blank.

FIG. 19 is a graph showing the results of measuring the relative activity values of 1-time screened Gaussian luciferases with respect to the tripeptides of the tripeptide library (#351 to #404) conceived from the amino acid sequence of α -8S globulin with respect to the blank. The relative activity values for each sample are represented by a circle symbol, with filled circles showing samples that show significantly lower values compared to the blank.

FIG. 20 shows the results of measuring the expression level of Fasn gene in 2 screenings of 35 tripeptides in the study of the tripeptides conceived from the amino acid sequence of α -8S globulin. The black bar shows samples with a significant decrease in the expression of the Fasn gene compared to the blank (described as Veh).

FIG. 21 shows the results of measuring the expression level of Fasn gene in 2 screens of 32 tripeptides in the study of the tripeptides conceived from the amino acid sequence of α -8S globulin. The black bar shows samples with a significant decrease in the expression of the Fasn gene compared to the blank (described as Veh).

FIG. 22 shows the results of measuring the expression level of Fasn gene in 3 screens of 9 tripeptides in the study of the tripeptides conceived from the amino acid sequence of α -8S globulin. The black bar shows samples with a significant decrease in the expression of the Fasn gene compared to the blank (described as Veh).

FIG. 23 shows the results of measuring the expression level of Fasn gene in 3 screens of 8 tripeptides in the study of the tripeptides conceived from the amino acid sequence of α -8S globulin. The black bar shows samples with a significant decrease in the expression of the Fasn gene compared to the blank (described as Veh).

FIG. 24 shows the results of measuring the expression level of Fasn gene in 3 screens of 8 tripeptides in the study of the tripeptides conceived from the amino acid sequence of α -8S globulin. The black bar shows samples with a significant decrease in the expression of the Fasn gene compared to the blank (described as Veh).

FIG. 25 is a graph showing the results of measuring the relative activity values of 1-pass screened Gaussian luciferases with respect to the tripeptides of the tripeptide library (#1 to #50) conceived from the amino acid sequence of α'/β -8S globulin with respect to the blank. The relative activity values for each sample are represented by a circle symbol, with filled circles showing samples that show significantly lower values compared to the blank.

FIG. 26 is a graph showing the results of measuring the relative activity values of 1-pass screened Gaussian luciferases with respect to the tripeptides of the tripeptide library (#51 to #95) conceived from the amino acid sequence of α'/β -8S globulin, relative to the blank. The relative activity values for each sample are represented by a circle symbol, with filled circles showing samples that show significantly lower values compared to the blank.

FIG. 27 is a graph showing the results of measuring the relative activity values of 1-pass screened Gaussian luciferases with respect to the tripeptides of the tripeptide library (#96 to #140) conceived from the amino acid sequence of α'/β -8S globulin with respect to the blank. The relative activity values for each sample are represented by a circle symbol, with filled circles showing samples that show significantly lower values compared to the blank.

FIG. 28 is a graph showing the results of measuring the relative activity values of 1-pass screened Gaussian luciferases with respect to the tripeptides of the tripeptide library (#141 to #183) conceived from the amino acid sequence of α'/β -8S globulin, relative to the blank. The relative activity values for each sample are represented by a circle symbol, with filled circles showing samples that show significantly lower values compared to the blank.

FIG. 29 shows the results of measuring the expression level of Fasn gene in 2 screens of 30 tripeptides in the study of the tripeptides conceived from the amino acid sequence of α'/β -8S globulin. The black bar shows samples with a significant decrease in the expression of the Fasn gene compared to the blank (described as Veh).

FIG. 30 shows the results of measuring the expression level of Fasn gene in 2 screens of 32 tripeptides in the study of the tripeptides conceived from the amino acid sequence of α'/β -8S globulin. The black bar shows samples with a significant decrease in the expression of the Fasn gene compared to the blank (described as Veh).

FIG. 31 shows the results of measuring the expression level of Fasn gene in 3 screens of 8 tripeptides in the study of the tripeptides conceived from the amino acid sequence of α'/β -8S globulin. The black bar shows samples with a significant decrease in the expression of the Fasn gene compared to the blank (described as Veh).

FIG. 32 shows the results of measuring the expression level of Fasn gene in 3 screens of 7 tripeptides in the study of the tripeptides conceived from the amino acid sequence of α'/β -8S globulin. The black bar shows samples with a significant decrease in the expression of the Fasn gene compared to the blank (described as Veh).

Detailed Description

In the present specification, the term "about" means a range of ± 10%, preferably ± 5%. In addition, numerical values that are boundary values of the ranges are regarded as being described in the present specification.

(peptide having inhibitory action on liver fat synthesis)

In some embodiments, the present invention provides peptides having an inhibitory effect on liver fat synthesis. More specifically, the peptide of the present embodiment is selected from 11 kinds of dipeptides (Ala-Gly, His-Asn, His-Ser, His-Thr, His-Trp, Val-Met, Trp-Glu, Trp-Lys, Tyr-Ser, and Tyr-Tyr) and 25 kinds of tripeptides (Val-Ile-Leu, Gly-Ser-Leu, Val-Leu-Gln, His-Ala-Gln, Arg-Ala-Val, Lys-Leu-Gly, Ile-Val-Ile, Lys-Pro-Ile, Leu-Val-Ile, Leu-Arg-Asp, Gln-Glu-Glu, Ser-Gly-Glu, Arg-Trp-Phe, Asp-Phe-Phe, Asp-Val-Phe-Phe, Pro-Phe-Tyr, Phe-Ile-Arg-Asp-Phe, and Ty, Asn-Gly-Arg, Ile-Ile-Pro, Ile-Asp-Arg, Ile-His-Arg, Ile-Asp-Arg, Asn-Arg-Val, Ser-Ser-Val and Val-Phe-Val). In some embodiments, the peptides of the present embodiments comprise more than one dipeptide. In other embodiments, the peptide of the present embodiment comprises more than one tripeptide. In other embodiments, the peptide of the present embodiments is a mixture of one or more dipeptides and one or more tripeptides.

In the present specification, the dipeptide and tripeptide may be represented by the following 1-letter abbreviations for amino acids.

Ala-Gly：AG，His-Asn：HN，His-Ser：HS，His-Thr：HT，His-Trp：HW，Val-Met：VM，Trp-Glu：WE，Trp-Lys：WK，Tyr-Lys：YK，Tyr-Ser：YS，Tyr-Tyr：YY，Val-Ile-Leu：VIL，Gly-Ser-Leu：GSL，Val-Leu-Gln：VLQ，His-Ala-Gln：HAQ，Arg-Ala-Val：RAV，Lys-Leu-Gly：KLG，Ile-Val-Ile：IVI，Lys-Pro-Ile：KPI，Leu-Val-Ile：LVI，Leu-Arg-Asp：LRD，Gln-Glu-Glu：QEE，Ser-Gly-Glu：SGE，Arg-Trp-Phe：RWF，Asp-Phe-Phe：DFF，Asp-Val-Phe：DVF，Pro-Phe-Tyr：PFY，Phe-Ile-Arg：FIR，Asn-Gly-Arg：NGR，Ile-Ile-Pro：IIP，Ile-Asp-Arg：IDR，Ile-His-Arg：IHR，Ile-Asp-Arg：IDR，Asn-Arg-Val：NRV，Ser-Ser-Val：SSV，Val-Phe-Val：VFV。

As a mechanism by which the peptide of the present embodiment exerts an inhibitory action on liver fat synthesis, it is presumed that the peptide of the present embodiment inhibits fat synthesis by inhibiting the expression of mrna (fasn) of fat synthase (FAS), which is a synthase for Fatty acids synthesized de novo in the liver.

The inhibition of hepatic fat synthesis can be confirmed by: for example, in the method described in "(2 screening methods)" described later, the amount of mrna (fasn) showed a significantly lower value than that in the peptide-free group.

The peptide of the present embodiment may be synthesized from amino acids, or may be obtained by hydrolyzing proteins. Examples of the method for hydrolyzing proteins include: protease-based hydrolysis, acid-based hydrolysis, alkali-based hydrolysis, and the like, preferably protease-based hydrolysis. In some embodiments, the peptide of the present embodiments is a synthetic peptide. In another embodiment, the peptide of the present embodiment is a peptide obtained by hydrolyzing a protein. In a further specific embodiment, the peptide of the present embodiment is a peptide obtained by hydrolyzing a protein with a protease.

As the raw material of the peptide, vegetable protein, animal protein, for example: examples of the raw material of the plant protein include beans such as soybean, pea, mung bean, chickpea, etc., grains such as rice, corn, wheat, etc., nuts such as almond, cashew nut, walnut, pistachio nut, hazelnut, macadamia nut, etc., and examples of the raw material of the animal protein include: beef, pork, chicken, egg, milk, etc. Specific examples of the raw material of the peptide include proteins derived from beans such as soybean, pea, mung bean, chickpea, and more specific examples include proteins derived from mung bean.

(protease)

In the case of protease-based protein hydrolysis, protease treatment is carried out using a slurry or an aqueous solution of the above-mentioned protein as a substrate. The protease used herein is not limited to animal sources, plant sources, or microbial sources, and can be appropriately selected from proteases classified into "metalloprotease", "acid protease", "thiol protease", and "serine protease" in the classification of proteases, and preferably proteases classified into "metalloprotease", "thiol protease", and "serine protease".

The classification of proteases is a method for classifying the types of amino acids based on the active center, which is generally performed in the field of enzyme science. As representative examples, the "metalloprotease" includes: examples of the "acidic protease" include neutral proteases of Bacillus (Bacillus), Streptomyces (Streptomyces), Aspergillus (Aspergillus), and "Thermoase": pepsin, Aspergillus (Aspergillus) acid protease, "Smithum AP", and the like, and examples of the "thiol protease" include: bromelain, papain, and the like, and examples of the "serine protease" include: trypsin, chymotrypsin, subtilisin (subtilisin), Streptomyces (Streptomyces) alkaline protease, "Alcalase", "Bioprase", and the like. Other enzymes can be classified by the action of pH and reactivity with inhibitors. Since the site of action of the enzyme having a different active center is greatly different from that of the substrate, the "cleavage residue" can be reduced, and the enzymatic decomposition product can be efficiently obtained. Or the enzyme decomposition product can be produced more efficiently by using enzymes of different origins (source organisms) in combination.

The reaction pH and the reaction temperature of the protease treatment may be set depending on the characteristics of the protease used, and the reaction pH may be generally set to be around the optimum pH, and the reaction temperature may be set to be around the optimum temperature. The reaction can be carried out at a reaction temperature of about 20 to 80 ℃ and preferably about 40 to 60 ℃. After the reaction, the residual enzyme activity is inactivated by heating at a temperature (about 60 to 170 ℃) sufficient for inactivating the enzyme.

The reaction solution after the protease treatment may be used as it is or concentrated, and may be used in the form of a dried powder by, for example, spray drying or freeze drying after sterilization. The sterilization is preferably heat sterilization, and the heating temperature is preferably 110-170 ℃, and more preferably 130-170 ℃. The heating time is preferably 3 to 20 seconds. The reaction solution may be adjusted to an arbitrary pH in advance, or a precipitate or suspension generated during the pH adjustment may be removed by centrifugation, filtration, or the like. In addition, purification may be further performed by activated carbon or an adsorption resin.

(acid or base based hydrolysis)

In acid-or alkali-based hydrolysis of protein hydrolysis, conditions such as substrate concentration, enzyme amount, treatment temperature, pH, and time may be appropriately set.

The peptide of the present embodiment can be used for producing a food composition for inhibiting liver fat synthesis. The peptide of the present embodiment can be used for producing an inhibitor of hepatic fat synthesis.

(food composition for suppressing liver fat synthesis)

In some embodiments, the present invention provides a food composition for inhibiting liver fat synthesis, comprising the peptide described in the above-mentioned "(peptide having liver fat synthesis inhibitory activity)". More specifically, the food composition for suppressing liver fat synthesis of the present embodiment is characterized by containing 11 dipeptides (Ala-Gly, His-Asn, His-Ser, His-Thr, His-Trp, Val-Met, Trp-Glu, Trp-Lys, Tyr-Ser and Tyr-Tyr) and 25 tripeptides (Val-Ile-Leu, Gly-Ser-Leu, Val-Leu-Gln, His-Ala-Gln, Arg-Ala-Val, Lys-Leu-Gly, Ile-Val-Ile, Lys-Pro-Ile, Leu-Val-Ile, Leu-Arg-Asp, Gln-Glu-Glu, Ser-Gly-Glu, Arg-Trp-Phe, Asp-Phe-Phe, Lys-Leu-Ile, Lys-Pro-Val-Ile, Leu-Arg, Asp-Val-Phe, Pro-Phe-Tyr, Phe-Ile-Arg, Asn-Gly-Arg, Ile-Ile-Pro, Ile-Asp-Arg, Ile-His-Arg, Ile-Asp-Arg, Asn-Arg-Val, Ser-Ser-Val and Val-Phe-Val). In some embodiments, the peptide contained in the food composition for inhibiting liver fat synthesis of the present embodiment comprises one or more dipeptides. In another embodiment, the peptide contained in the food composition for inhibiting liver fat synthesis according to the present embodiment includes one or more tripeptides. In another embodiment, the peptide contained in the food composition for inhibiting liver fat synthesis according to the present embodiment is a mixture of one or more dipeptides and one or more tripeptides.

The food composition for inhibiting liver fat synthesis according to the present embodiment may be produced in the form of a supplement (supplement), a food additive, or a food additive, using the above-mentioned peptide alone, or appropriately mixed with other raw materials as necessary. When the food composition is provided in the form of a supplement, it can be used in various forms such as liquid, powder, granule, Tablet (Tablet), capsule, etc. When the food composition is provided in the form of a food additive, it can be used in various forms such as liquid, paste, gel, powder, granule, solid, etc. The food composition is not hindered when it is mixed with solid foods such as cookies, cake, bread, food bar, meat product, etc., and can be dissolved in water to make beverage or mixed with flowing or semi-solid foods such as yogurt, pudding, and jelly. The other raw materials to be mixed in the food composition of the present embodiment are not particularly limited as long as they can be used as food additives or foods. Examples of other raw materials include: vinegar, bean paste, soy sauce, amino acid, etc.; sour agents such as acetic acid, citric acid, malic acid and lactic acid; sweeteners such as aspartame, sucralose, acesulfame potassium and stevia extract; a bittering agent; a spice; a preservative; a pigment; a fragrance; salts; saccharides such as glucose, fructose, sucrose and lactose; grease; an antioxidant; vitamins; minerals; a stabilizer; a thickener; an extender; gelling agents such as pectin, gellan gum, agar and gelatin; and excipients such as lactose, starch, dextrin, cellulose, etc. In a more specific embodiment, the food composition of this embodiment is in the form of a supplement. As further specific examples, there may be mentioned: a supplement in which only the peptide is encapsulated, a supplement in which an excipient is added to the peptide to prepare a powder or a granule, a supplement in which an excipient is added to the peptide to prepare a tablet, a jelly-like supplement in which a gelling agent is added to the peptide and the peptide is packaged, and the like.

The content of the peptide in the food composition for inhibiting liver fat synthesis according to the present embodiment is not particularly limited, and examples thereof include: about 0.1, 0.2, 0.3, 0.5, 0.7, 1, 1.2, 1.5, 1.7, 2, 2.5, 3, 3.5, 4, 4.5, 5, 7, 9, 10, 12, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 92, 95, 97, 98, 99, 100% by weight and the like relative to the food composition. The content of any of these values may be in any range of upper and lower limits. The intake amount of the food composition for inhibiting liver fat synthesis according to the present embodiment is not particularly limited, and examples thereof include: the amount of the peptide in the food composition is about 0.001 to 100mg/kg body weight, for example about 0.01 to 50mg/kg body weight, about 0.1 to 25mg/kg body weight, about 0.5 to 10mg/kg body weight, or the like, per 1 time.

(liver fat synthesis inhibitor)

In some embodiments, the present invention provides a liver fat synthesis inhibitor comprising the peptide described in the above-mentioned "(peptide having a liver fat synthesis inhibitory effect)". More specifically, the liver fat synthesis inhibitor of the present embodiment is characterized by containing, as active ingredients, 11 dipeptides (Ala-Gly, His-Asn, His-Ser, His-Thr, His-Trp, Val-Met, Trp-Glu, Trp-Lys, Tyr-Ser, and Tyr-Tyr) and 25 tripeptides (Val-Ile-Leu, Gly-Ser-Leu, Val-Leu-Gln, His-Ala-Gln, Arg-Ala-Val, Lys-Leu-Gly, Ile-Val-Ile, Lys-Pro-Ile, Leu-Val-Ile, Leu-Arg-Asp, Gln-Glu-Glu, Ser-Gly-Glu, Arg-p-Phe, Asp-Phe-Phe, Asp-Val-Phe, Asp-Phe-Leu-Phe, Pro-Phe-Tyr, Phe-Ile-Arg, Asn-Gly-Arg, Ile-Ile-Pro, Ile-Asp-Arg, Ile-His-Arg, Ile-Asp-Arg, Asn-Arg-Val, Ser-Ser-Val and Val-Phe-Val). In some embodiments, the peptide contained in the liver fat synthesis inhibitor of the present embodiment includes one or more dipeptides. In another embodiment, the peptide contained in the liver fat synthesis inhibitor of the present embodiment includes one or more tripeptides. In another embodiment, the peptide contained in the liver fat synthesis inhibitor of the present embodiment is a mixture of one or more dipeptides and one or more tripeptides.

The liver fat synthesis inhibitor of the present embodiment can be produced using only the above-mentioned peptide, or appropriately mixed with other raw materials as necessary. Typically, the liver fat synthesis inhibitor of the present embodiment may be a pharmaceutical composition.

The dosage form of the liver fat synthesis inhibitor of the present embodiment is not particularly limited, and examples thereof include: oral administration agents such as granules, fine granules, tablets and the like; liquid, i.e. injectable powder such as instant powder; transdermal preparations such as ointment, liquid, paste, and gel; suppositories and the like.

The method of administering the liver fat synthesis inhibitor of the present embodiment is not particularly limited, and examples thereof include: oral administration, intravenous administration, intramuscular administration, topical administration to the affected area, transdermal administration, rectal administration, and the like. As a more specific example of the administration method, oral administration may be cited.

The liver fat synthesis inhibitor of the present embodiment may contain, in addition to the peptide as an active ingredient, other pharmaceutically acceptable raw materials, for example: pharmaceutically acceptable carriers, excipients, diluents, isotonicity agents, additives, disintegrants, binders, stabilizers, coating agents, dispersion media, bulking agents, pH buffering agents, lubricants, glidants, lubricants, flavoring agents, sweeteners, solubilizing agents, solvents, gelling agents, nutritional agents, and the like. The absorption property and blood concentration of the liver fat synthesis inhibitor of the present embodiment may be affected by using such other raw materials, and the pharmacokinetics in vivo may be changed. Specific examples of other raw materials include: water, physiological saline, animal fat, vegetable fat, lactose, starch, gelatin, crystalline cellulose, gum, talc, magnesium stearate, hydroxypropyl cellulose, polyalkylene glycol, polyvinyl alcohol, glycerin, etc.

The content of the peptide in the liver fat synthesis inhibitor of the present embodiment is not particularly limited, and examples thereof include: about 0.1, 0.2, 0.3, 0.5, 0.7, 1, 1.2, 1.5, 1.7, 2, 2.5, 3, 3.5, 4, 4.5, 5, 7, 9, 10, 12, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 92, 95, 97, 98, 99, 100% by weight or the like with respect to the total amount of the liver fat synthesis inhibitor. The amount of addition may be in any range of any of these values as upper and lower limits. The amount of the liver fat synthesis inhibitor to be administered in the present embodiment is not particularly limited, and examples thereof include: about 0.001mg/kg to 100mg/kg of body weight, for example, about 0.01 to 50mg/kg of body weight, about 0.1 to 25mg/kg of body weight, about 0.5 to 10mg/kg of body weight, etc., based on the amount of the peptide, per 1 time.

The frequency of administration of the liver fat synthesis inhibitor of the present embodiment is not particularly limited, and examples thereof include administration 1 to a plurality of times a day, for example, 2, 3, 4, or 5 times a day, and continuous administration by drip injection or the like.

(method of inhibiting liver fat synthesis)

In some embodiments, the present invention provides a method for inhibiting liver fat synthesis in a subject, the method comprising ingesting the food composition for inhibiting liver fat synthesis described above, or administering the liver fat synthesis inhibitor described above.

The term "subject" used in the present specification may include human or non-human animals, and may exemplify, for example: human, mouse, rat, monkey, pig, dog, rabbit, hamster, guinea pig, and the like, but are not limited thereto.

In some embodiments, the term "subject" in this embodiment is a subject in need of inhibition of fat synthesis in the liver. More specifically, examples of the symptoms requiring inhibition of fat synthesis in the liver include: obesity, fatty liver, fatty hepatitis, liver cirrhosis, diabetes, cardiomyopathy, arteriosclerosis, etc. That is, in other embodiments, the methods of the present embodiments provide methods of treating or preventing a condition requiring inhibition of fat synthesis in the liver.

In other embodiments, the methods of the invention comprise the concomitant administration of a pharmaceutical product for the treatment or prevention of symptoms of obesity, fatty liver, fatty hepatitis, liver cirrhosis, diabetes, cardiomyopathy, arteriosclerosis, and the like. The administration period may be simultaneous administration, a food composition for inhibiting liver fat synthesis or an inhibitor of liver fat synthesis followed by a pharmaceutical product, or the reverse order.

All the descriptions (for example, the specification of the form, the formulation, the intake amount, the administration amount, and the like) in the above embodiments of "the food composition for inhibiting liver fat synthesis" and "the food composition for inhibiting liver fat synthesis" are also applicable to the method of the present embodiment.